Lymphoma
Conditions
Keywords
Lymphoma, Relapsed Lymphoma, MLN0128, Blood sugar, Glucometer, TK228
Brief summary
The goal of this clinical research study is to learn if TAK-228 can help to control relapsed lymphoma. The safety of this drug will also be studied.
Detailed description
Study Drug Administration: If you are found to be eligible for this study, you will begin taking capsules of TAK-228 in 28-day cycles. You will take the drug 1 time every day at about the same time. You should take the drug with about a cup (8 ounces) of water after eating a light meal. You should fast for 2 hours before and 1 hour after each dose. If you vomit or have other digestive side effects that prevent you from taking a dose, that dose should be skipped. If you vomit up a dose, that dose should not be retaken. In both cases, wait until the next day to take another dose. In no case should you double or repeat a dose. You should record any vomiting in the dose diary the study staff provides you with. Study Visits: Within 3 days before you start taking TAK-228, blood (about 2 teaspoons) will be drawn for biomarker testing. Biomarkers are found in the blood/tissue and may be related to your reaction to the study drug. On Day 1 of each cycle: * You will have a physical exam. * Blood (about 2-3 tablespoons) will be drawn for routine tests. You must fast for 4 hours before this blood draw. Some of these draws will be used for a diabetes test. If you can become pregnant, part of this sample will be used for a pregnancy test. * Blood (about 2 teaspoons) will be drawn for biomarker testing (Cycles 1 and 2 only). * You will have an EKG (within 3 days of each cycle after Cycle 1). On Days 8 and 22 of Cycle 1, you will have a physical exam. On Day 15 of Cycle 1: * You will have a physical exam * Blood (about 2-3 tablespoons) will be drawn for routine tests. Within 5 days before Day 1 of Cycle 3, then every even-numbered cycle after that (Cycles 4, 6, 8, and so on), you will have CT scans, chest x-rays, and a bone marrow biopsy/aspiration to check the status of the disease. If the study doctor thinks it is in your best interest, you will have PET/CT scans every 2 cycles to check the status of the disease. Blood Sugar Testing: You will be given a glucometer to check your pre-dose blood sugar levels at home every day. The study staff will teach you how to use the glucometer and what an abnormal reading looks like. You must tell the study staff right away if you have any abnormal readings. The frequency of in-home fasting glucose testing may be reduced to once weekly if the doctor thinks it is needed. Length of Study: You may continue to receive the study drug for up to 12 cycles. You will no longer be able to take the drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. Your participation in this study will be over after the follow-up phone calls have finished. End-of-Treatment Visits: About 1 week after you stop taking the study drug: * You will have a physical exam * Blood (about 2-3 tablespoons) will be drawn for routine tests and to test for diabetes. This will include a pregnancy test if you are able to become pregnant. * You will have an EKG. About 2 weeks after you stop taking the study drug, you will have CT scans and chest x-rays to check the status of the disease. If the study doctor thinks it is needed, you will also have a bone marrow biopsy/aspiration to check the status of the disease. Within 2 weeks after you stop taking the study drug, blood (about 2 teaspoons) will be drawn for biomarker testing. This is an investigational study. TAK-228 is not FDA approved or commercially available. It is currently being used for research purposes only. The study doctor can describe how the study drug is designed to work. Up to 75 participants will be enrolled in this study. All will take part at MD Anderson.
Interventions
DRUGTAK228
Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
OTHERBlood Sugar Testing
Participant given a glucometer to check pre-dose blood sugar levels at home every day.
Sponsors
Takeda
M.D. Anderson Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Each patient must meet all of the following inclusion criteria to be enrolled in the study: 1. Male or female patients 18 years or older. 2. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care. 3. Female patients who: are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR if they are of childbearing potential, agree to practice 1 effective methods of contraception and one additional effective (barrier) method, at the same time, from the time of signing the informed consent through 90 days (or longer, as mandated bu local labeling \[eg,USPI, SmPC, etc;\]) after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient (Periodic abstinence \[e.g, calendar, ovulation, symptothermal, postovulation methods\] and withdrawal,spermicides only, ad lactational amenorrhea are not acceptable methods of contraception.Female and male condoms should not be used together. 4. Male patients, even if surgically sterilized (ie, status post-vasectomy), who: agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient (Periodic abstinence \[e.g, calendar, ovulation, symptothermal, postovulation methods for the female partner\] and withdrawal, spermicides only, ad lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together; Agree not to donate sperm during the course of this study or 120 days after receiving their last dose of study drug 5. Patients must have a diagnosis of prior treated diffuse large b-cell lymphoma, mantle cell lymphoma, transformed lymphoma, follicular lymphoma (any grade), small lymphocytic lymphoma, marginal zone lymphoma, or Hodgkin lymphoma with at least 2 lines of therapy without a curative treatment options. 6. Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status \</= 2. 7. Adequate organ function, as specified below, within 3 weeks before the first dose of study drug: a) Bone marrow reserve consistent with: absolute neutrophil count (ANC) \>/=1.5 x 10\^9/L; platelet count \>/=100 x 10\^9/L; hemoglobin \>/=9 g/dL without transfusion within 1 week preceding study drug administration; b) Hepatic: total bilirubin \< /=1.5 x upper limit of normal (ULN), transaminases (aspartate aminotransferase-AST and alanine aminotransferase ALT) \</= 2.5 x ULN (\</= 5 x ULN if liver metastases are present); c) Renal: creatinine clearance \>/= 50 mL/min based either on Cockcroft-Gault estimate or based on urine collection (12 or 24 hour); d) Metabolic: fasting serum glucose (\</=130 mg/dL) and fasting triglycerides \</=300 mg/dL; 8. Ability to swallow oral medications; 9. Measurable disease, defined as \>/=1.5 cm on imaging assessment.
Exclusion criteria
1. Eligible for therapy for the lymphoid malignancy which has a high likelihood of a curative result in the opinion of the investigator. 2. Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period 3. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol 4. Concurrent malignancies except basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ treated with curative intent. Any cancer from which the patient has been disease free for at least 2 years is permissible. 5. Treatment with any investigational products within 14 days before the first dose of study drug 6. Failed to recover to baseline or stable grade 1 from the reversible effects of prior anticancer therapies with the exception of alopecia. 7. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK228; such as significant chronic diarrhea. In addition, patients with enteric stomata are also excluded. 8. Poorly controlled diabetes mellitus defined as HbA1c \> 7%; subjects with a history of transient glucose intolerance due to corticosteroid administration are allowed in this study if all other inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Assessment (RA) | Time frame for response assessment was from Baseline to end of treatment or progression of disease up to 1 year. | RA was defined by Lugano Criteria & based on CT scans obtained at screening & after completion of every 2 cycles of therapy. Complete Radiographic Response Target Nodes must regress to \<=1.5cm in longest dimension,No extralymphatic sites of disease. PR \>=50% decrease in sum of the product of diameters of up to 6 target measurable nodes and extranodal sites. When a lesion is too small to measure on CT, 5 mmx5mm is assigned. When not visible on CT, assign 0x0 mm. For a node 5mmx5mm use actual measurement. SD\< 50% decrease in sum of the product of diameters of up to 6 target measurable nodes & extranodal sites, no criteria for disease progression are met. Progressive disease requires one of the following:An individual node must be abnormal with: LDi 1.5cm & Increase by 50% from PPD nadir & an increase in LDi or SDi from nadir 0.5cm for lesions 2cm,1cm for lesions 2cm. In case of splenomegaly, the splenic length must increase by \>=50% of the extent of its prior increase beyond baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Adverse Events | Baseline to end of treatment or progression of disease | Progression free survival, duration of response and overall survival analysis could not be properly evaluated due to patients being taken off study early due to progression of disease but safety and tolerability were reported through safety event reports, please see AEs-serious and non-serious section for this. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory Objective to Define Change of mTOR Pathway Protein Phosphorylation and the Incidence of Activating Mutations in MTOR and Related Genes. | Baseline to end of treatment or progression of disease | Assessed with reverse phase protein arrays after exposure to TAK228, |
Countries
United States
Participant flow
Recruitment details
Recruitment was open from 03/01/2017 to 11/27/2017
Pre-assignment details
No significant events in the study occurred after enrollment, prior to assignment to arm/group
Participants by arm
| Arm | Count |
|---|---|
| Aggressive NHL(DLBCL/MCL/Transformed Large Cell Lymphoma/FL gr Aggressive NHL(DLBCL/MCL/transformed large cell lymphoma/FL grade 3b | 4 |
| Indolent NHL:FL grade1-3a,SLL,MZL Indolent NHL:FL grade1-3a,SLL,MZL | 0 |
| Hodgkin Lymphoma Hodgkin lymphoma | 0 |
| Total | 4 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Progressive disease | 2 | 0 | 0 |
| Overall Study | Screen Failure | 2 | 0 | 0 |
Baseline characteristics
| Characteristic | Aggressive NHL(DLBCL/MCL/Transformed Large Cell Lymphoma/FL gr | Total |
|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 1 Participants | 1 Participants |
| Region of Enrollment United States | 4 Participants | 4 Participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants |
| Sex: Female, Male Male | 3 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 2 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 2 / 2 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 1 / 2 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Response Assessment (RA)
RA was defined by Lugano Criteria & based on CT scans obtained at screening & after completion of every 2 cycles of therapy. Complete Radiographic Response Target Nodes must regress to \<=1.5cm in longest dimension,No extralymphatic sites of disease. PR \>=50% decrease in sum of the product of diameters of up to 6 target measurable nodes and extranodal sites. When a lesion is too small to measure on CT, 5 mmx5mm is assigned. When not visible on CT, assign 0x0 mm. For a node 5mmx5mm use actual measurement. SD\< 50% decrease in sum of the product of diameters of up to 6 target measurable nodes & extranodal sites, no criteria for disease progression are met. Progressive disease requires one of the following:An individual node must be abnormal with: LDi 1.5cm & Increase by 50% from PPD nadir & an increase in LDi or SDi from nadir 0.5cm for lesions 2cm,1cm for lesions 2cm. In case of splenomegaly, the splenic length must increase by \>=50% of the extent of its prior increase beyond baseline.
Time frame: Time frame for response assessment was from Baseline to end of treatment or progression of disease up to 1 year.
Population: No analysis could be performed due to 2 participants failed screening and 2 participants disease progressed before analysis could be performed
Secondary
Number of Participants With Adverse Events
Progression free survival, duration of response and overall survival analysis could not be properly evaluated due to patients being taken off study early due to progression of disease but safety and tolerability were reported through safety event reports, please see AEs-serious and non-serious section for this.
Time frame: Baseline to end of treatment or progression of disease
Population: Adverse events were evaluated for the time patients were on study however due to early progression of disease, patients did not finish the treatment and adverse events reported were not conclusive of toxicity related to drug. Updated to two participants for the secondary outcome.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Aggressive NHL(DLBCL/MCL/Transformed Large Cell Lymphoma/FL gr | Number of Participants With Adverse Events | 2 Participants |
Other Pre-specified
Exploratory Objective to Define Change of mTOR Pathway Protein Phosphorylation and the Incidence of Activating Mutations in MTOR and Related Genes.
Assessed with reverse phase protein arrays after exposure to TAK228,
Time frame: Baseline to end of treatment or progression of disease
Population: Exploratory objective was not analyzed because patients came off study before it could be analyzed, no data were collected.